Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MITF | O75030 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.36 |
| ▸ | CBFB | Q13951 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9012929 | 0.98 | KDM4E (0.44) | POLBKDM4EALDH1A1LMNAMITF | |
| SCHEMBL3668687 | 0.87 | POLB (0.49) | POLBKDM4EALDH1A1LMNAMITF | |
| SCHEMBL3035099 | 0.86 | EGFR (0.41) | POLBKDM4EALDH1A1LMNAMITF | |
| SCHEMBL307339 | 0.86 | TSHR (0.40) | POLBKDM4EALDH1A1LMNAMITF | |
| SCHEMBL3665219 | 0.84 | KDM4E (0.46) | POLBKDM4EALDH1A1LMNAGAA | |
| SCHEMBL3671200 | 0.82 | MMP2 (0.49) | POLBKDM4EALDH1A1LMNAMITF | |
| SCHEMBL307615 | 0.82 | KDM4E (0.40) | POLBKDM4EALDH1A1LMNAMITF | |
| SCHEMBL8044086 | 0.82 | TSHR (0.46) | POLBKDM4EALDH1A1LMNAMITF | |
| SCHEMBL3041752 | 0.82 | PTPN1 (0.41) | POLBKDM4EALDH1A1LMNAMITF | |
| SCHEMBL9501876 | 0.79 | RAB9A (0.51) | POLBALDH1A1RAB9AMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-2240485-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Pharmaceutical Company Limited (JP) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-0646583-A1 | Derivatives of Imidezol-4-yl piperidine, their preparation and use in therapy | SYNTHELABO (FR) | 1995-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | POLB 4669/4885KDM4E 2435/4885ALDH1A1 2741/4885 |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRH, CRHR1, CRHR2 | POLB 4699/4885KDM4E 3544/4885ALDH1A1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.